TNYA news

Latest 3 stories · newest Nov 4, 2026

TNYA

Tenaya Receives FDA RMAT for Cardiac Gene Therapy TN-401

Tenaya announced regulatory biomarker for heart disease and provided business updates ahead of quarterly data. The stock is expected to react to key interim trial results and pivotal trial guidance, expected by year-end.

Regulatory Nov 4, 2026 sentiment +0.40 SEC filing ↗

TNYA

Tenaya Therapeutics appoints Eric Hyllengren as Chief Financial Officer

Tenaya Therapeutics named Eric Hyllengren as its new CFO. This executive suite addition comes as the biopharmaceutical company advances its therapeutic pipeline.

Leadership Jun 29, 2026 sentiment +0.50 SEC filing ↗

TNYA

Tenaya Therapeutics amends 2021 equity incentive plan

Tenaya Therapeutics filed an amended and restated 2021 equity incentive plan governing stock options, RSUs, and other equity awards for employees and directors. The plan update reflects standard governance changes for equity compensation administration.

Other May 29, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same TNYA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/TNYA/newsSTART FREE